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Background: Delay in symptomatic presentation leading to advanced stage at diagnosis may contribute to poor cancer survival.
To inform public health approaches to promoting early symptomatic presentation, we aimed to identify risk factors for delay in
presentation across several cancers.
Methods: We surveyed 2371 patients with 15 cancers about nature and duration of symptoms using a postal questionnaire. We
calculated relative risks for delay in presentation (time from symptom onset to first presentation43 months) by cancer, symptoms
leading to diagnosis and reasons for putting off going to the doctor, controlling for age, sex and deprivation group.
Results: Among 1999 cancer patients reporting symptoms, 21% delayed presentation for 43 months. Delay was associated with
greater socioeconomic deprivation but not age or sex. Patients with prostate (44%) and rectal cancer (37%) were most likely to
delay and patients with breast cancer least likely to delay (8%). Urinary difficulties, change of bowel habit, systemic symptoms
(fatigue, weight loss and loss of appetite) and skin symptoms were all common and associated with delay. Overall, patients with
bleeding symptoms were no more likely to delay presentation than patients who did not have bleeding symptoms. However,
within the group of patients with bleeding symptoms, there were significant differences in risk of delay by source of bleeding: 35%
of patients with rectal bleeding delayed presentation, but only 9% of patients with urinary bleeding. A lump was a common
symptom but not associated with delay in presentation. Twenty-eight percent had not recognised their symptoms as serious and
this was associated with a doubling in risk of delay. Embarrassment, worry about what the doctor might find, being too busy to go
to the doctor and worry about wasting the doctor’s time were also strong risk factors for delay, but were much less commonly
reported (o6%).
Interpretation: Approaches to promote early presentation should aim to increase awareness of the significance of cancer
symptoms and should be designed to work for people of the lowest socioeconomic status. In particular, awareness that rectal
bleeding is a possible symptom of cancer should be raised.
Inequalities in cancer survival may be explained by differences in
tumour biology, access to effective treatment and stage at
diagnosis. Delay in presentation with symptoms among patients
with cancer is likely to contribute to late stage at diagnosis
and, thereby, poorer survival (Richards et al, 1999; Neal, 2009;
De Angelis et al, 2014).
How long a cancer patient takes to present may be influenced by
several factors, including the nature of the symptoms, awareness of
the significance of the symptoms, perception of personal risk of
cancer, and physical, social and psychological barriers to health
care (Ramirez et al, 1999; Macleod et al, 2009). In the UK,
awareness in the general population that the risk of cancer
increases with age is low and reporting that embarrassment and
worry about wasting the doctor’s time might put them off going to
the doctor is common compared with similar countries (Forbes
et al, 2013). However, we do not yet have evidence to explain fully
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why some cancer patients delay symptomatic presentation. This
evidence is important to inform interventions to promote early
presentation (Austoker et al, 2009).
Approaches to promoting early presentation generally focus on
specific cancers (Austoker et al, 2009; Athey et al, 2011; Forbes
et al, 2011). However, when a patient experiences symptoms, they
may not associate these with the possibility of a specific cancer and
seek help, even if they have been exposed to a campaign –
particularly if their symptoms are not specific for cancer, for
example, weight loss or abdominal pain. Campaigns to promote
early symptomatic presentation of cancer may have more
impact on mortality if they address the risk factors for delay in
presentation in general.
We aimed to identify risk factors for the delay in presentation by
socio-demographic characteristics, cancer type, symptom type and
reported reasons for not going to the doctor across a population of
cancer patients, to inform the development of public health
approaches to promote early presentation.
MATERIALS AND METHODS
Sampling. Cancer patients were selected from people who had
taken part in the English Department of Health’s Cancer Patient
Experience Survey in mid-2010 (Department of Health, 2010). This
included all adult cancer patients who had received treatment at 1
of 158 National Health Service (NHS) hospitals in England from
January-March 2010. These patients had been sent a postal
questionnaire asking about their experiences of health care, and
67 713 patients responded (66%).
Of the respondents, 53 104 agreed that they could be
recontacted for further surveys. We identified who among these
had died using the national Demographic Batch Service system
(Health and Social Care Information Centre, 2014), which
maintains an up-to-date list of all NHS patients. We randomly
sampled 200 patients, each with 1 of 22 cancer types (Table 1
provides International Classification of Diseases codes), from those
alive in November 2011. Only 181 patients with pancreatic cancer
were alive in November 2011, so we sent a questionnaire to all of
them. The cancer types were selected to include common cancers
and some rarer cancers for which we had identified a lack of
information about nature and duration of symptoms. We aimed
for a sample size of 3000 for patients with 1 of all 22 cancer types,
which would provide reasonable precision around estimates of
frequency of symptoms for the entire population of cancer patients.
For the analysis described in this paper, we included only
patients with 1 of 15 cancers where475% patients who had taken
part in the Cancer Patient Experience Survey 2010 were still alive
in November 2011 (Table 1). This was to minimise ‘survivor’ bias
introduced by surveying only those who were alive at least 16
months after the Cancer Patient Experience survey. Cancers
included in the analysis were cancers of breast, colon, rectum,
cervix, endometrium, oral cavity, kidney/ureter, bladder and
prostate; malignant melanoma; sarcoma; chronic myeloid leukae-
mia, chronic lymphocytic leukaemia, non-Hodgkin’s lymphoma,
and myeloma. These 15 cancer types represent 61% of the
population of cancer patients in England (excluding non-
melanoma skin cancer) (Office for National Statistics, 2011). The
most common cancers that we excluded from the analysis were
lung and upper gastrointestinal cancers.
The questionnaire. The patients were sent a self-complete
questionnaire asking about the nature of the symptoms that had
caused them to see a doctor and led to diagnosis. Patients were
asked to identify symptoms from a list, because this type of data
could be analysed more reliably than responses to open questions.
Participants could tick more than one symptom. We developed
cancer-specific versions of the questionnaire (shown in
Supplementary Material), so as to keep the list of symptoms short.
The symptom lists were developed with the input of clinical experts
in the relevant cancers.
The questionnaire asked participants how long it was from
noticing the symptom that led to diagnosis to presenting to a
doctor (o2 weeks/2–4 weeks/44 weeks to 3 months/43 months
to 6 months/46 months to 12 months/41 year), the date the
presenting symptom started and date of first going to a doctor. The
questionnaire asked what had put the patient off seeing a doctor
(based on those in the validated Awareness and Beliefs about
Cancer measure (Simon et al, 2012) and Cancer Research UK
Cancer Awareness Measure (Stubbings et al, 2009)).
Questionnaires for breast, bowel and cervical cancer also asked
about whether the patient had been diagnosed via a NHS Cancer
Screening Programme.
The questionnaire was based on our previous studies of breast
and cervical cancer (Burgess et al, 1998; Lim et al, 2013). The
questionnaires were piloted and cognitively tested (Campanelli,
1997) in three rounds. This aimed to ensure that the questions
were easy to complete, acceptable and understandable, and to test
the ability of patients to recall events. The patients, recruited
through Macmillan Cancer Support, were first sent the ques-
tionnaires. Trained interviewers then conducted telephone inter-
views, asking the patients to describe in their own words what they
thought the questions were asking, and ‘think aloud’ to describe
how they would answer.
Table 1. Proportions of patients alive in November 2011, of those who
took part in the National Cancer Patient Experience Survey 2010, and






ICD-10 Cancer type n (%) n (%)
Included in the analysis of risk factors for delay in presentation
C43 Malignant melanoma 963 (92.3) 159 (79.9)
C50 Breast (women) 10,078 (91.1) 164 (82.4)
C67 Bladder 4,637 (89.6) 160 (80.4)
C92.1 Chronic myeloid leukaemia 218 (89.3) 159 (79.5)
C54 Body of uterus 865 (87.6) 158 (79.4)
C82–83 Non-Hodgkin’s lymphoma 1,730 (87.5) 161 (80.9)
C53 Cervix 287 (85.2) 133 (67.2)
C61 Prostate 3,489 (84.1) 170 (85.0)
C91.1 Chronic lymphocytic leukaemia 700 (82.1) 161 (80.5)
C64–66 Kidney and ureter 702 (82.0) 154 (78.6)
C19–20 Rectum 2,195 (81.4) 175 (88.4)
C18 Colon 3,039 (80.0) 166 (84.3)
C40–41, C49 Sarcoma 280 (78.9) 140 (70.7)
C90 Myeloma 1,695 (78.8) 150 (76.1)
C01–06 Oral cavity 370 (77.4) 161 (81.7)
Not included in the analysis of risk factors for delay in
presentation
C91.0, C92.0 Acute leukaemia 477 (68.1) 154 (80.2)
C56 Ovary 927 (65.3) 152 (77.2)
C77–79 Secondary cancer 1,959 (60.4) 144 (74.6)
C16 Stomach 425 (55.7) 140 (73.7)
C15 Oesophagus 533 (50.5) 155 (81.2)
C34 Lung 1,230 (48.3) 142 (77.2)
C25 Pancreas 181 (38.9) 113 (71.5)
aA further 88 patients died during fieldwork; these have been removed from the
denominator in calculating response rates.
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Data collection. A postal survey was carried out between
November 2011 and January 2012. We sent two reminders to
non-responders.
Statistical analysis. We excluded all patients who reported being
diagnosed via a screening programme (i.e., breast, bowel, cervix) or
who reported no symptoms. We assigned each patient an Index of
Multiple Deprivation (IMD) based on postcode (Public Health
Observatory, 2011). The IMD provides a measure of socio-
economic deprivation based on the characteristics of the area of
residence of each individual (Department for Communities and
Local Government, 2014), a higher score indicating greater
deprivation. We categorised people into quintiles of IMD in
England.
We categorised symptoms into nine categories (or ‘other)
(Supplementary Box S1, online supplement), to reflect a patient’s
experience rather than the pathology underlying the symptoms.
We coded free text symptoms into these categories where possible.
We weighted the percentages reporting each symptom for the
incidence of the cancer (using 2009 national cancer registration
data (Office for National Statistics, 2011) to give percentages more
representative of the whole population of cancer patients.
We calculated duration of symptoms leading to diagnosis based
on the response to the question: ‘In these first few questions we
would like to know about the MAIN health problems or symptoms
that made you go to see the GP (family doctor), or made you go to
accident and emergency, and that led to you being diagnosed with
cancery. How long was it from the time you noticed these MAIN
health problems or symptoms and first seeing a GP or hospital
doctor?’ (Questionnaires provided in Supplementary Material).
Where patients had not responded to the question about duration
of symptoms, we calculated duration from dates provided by the
patient, if they had given day, month and year for both onset of
symptoms and date of seeing a doctor. We considered43 months
from onset of symptoms to presentation as a ‘delay’, as this is
conventional and likely to represent a clinically important delay
(Richards et al, 1999).
We calculated relative risks for delay in presentation, fitting
log-binomial regression models using the Stata command glm, by
cancer, presenting symptom and reasons for putting off going to
the doctor. We controlled for age, sex and deprivation group,
because we judged in advance that these might influence time to
presentation (Ramirez et al, 1999; Macleod et al, 2009).
As a survey of perceptions of NHS patient care designed to
improve services, no formal ethics approval was sought for the
Cancer Patient Experience Survey by the Department of Health.
However, all patients approached, as part of our survey had given
written consent to being recontacted.
RESULTS
Completeness of sample. In late 2011, the proportion of those
who took part in the Cancer Patient Experience Survey 2010 who
were alive at the time of our survey varied by cancer (Table 1),
from 92% in malignant melanoma to 77% for cancer of the oral
cavity.
Response. We sent questionnaires to 4381 patients. These
included 3000 patients with 1 of the 15 cancer types selected for
this analysis. We received completed questionnaires from 2371
(79%) of these patients. Response varied by cancer, from 67%
(cervix cancer) to 88% (rectal cancer) (Table 1).
Participants. In total, 1999 patients reported any symptoms and
that they had not been diagnosed via an NHS Cancer Screening
Programme. All had been diagnosed in the year before the Cancer
Patient Experience Survey 2010. Of the patients reporting
symptoms, 1077 (54%) were male, 534 (27%) were aged 70þ
and 1539 (77%) were aged 50þ ; all were of White ethnic group. In
the population of cancer patients registered in England in 2009
with 1 of the 15 cancer types, 51% were male, 47% were aged 70þ
and 89% were aged 50þ (Office for National Statistics, 2011).
Median IMD was 13.8 (English median is 15) (Public Health
Observatory, 2011).
What were the symptoms that led to a diagnosis of cancer?
Table 2 shows the proportions of patients with each cancer type
reporting each type of symptom. There were relatively few women
with breast or cervical cancer because many of these reported that
they had been diagnosed by NHS Cancer Screening Programmes.
Table 2 also shows the frequency of symptoms overall and by
cancer. The five commonest presenting symptoms were pain
(reported by 29%), lump (28%), bleeding (23%), difficulty with
urination (18%) and systemic symptoms (17%). Among the
patients with pain, musculoskeletal pain and abdominal pain were
equally common (each reported by 9% of the total). Rectal bleeding
was the commonest type of bleeding (10%) followed by urinary
(8%) and vaginal bleeding (4%). The commonest systemic
symptom was fatigue (13%). Eating-related symptoms and chest
symptoms were uncommon, which is likely to be because we
excluded patients with upper gastrointestinal and lung cancers.
What put you off going to the doctor? In total, 965 patients
(48%) reported anything that put them off going to the doctor
(Table 3), most commonly not realising that the symptom was
serious (27%). Most patients reporting this had common
presenting symptoms: 33% pain, 29% systemic symptoms, 22%
lump or swelling, and 21% bleeding. Other reasons for putting off
going to the doctor were rarely reported, the most common being
worry about wasting the doctor’s time, reported by 6%.
How long was it from noticing the symptoms to first seeing a
doctor? We had data on duration of symptoms for 1835 patients
(92%). The proportion with these data available varied by cancer,
being most complete in non-Hodgkin’s lymphoma (96%) and least
complete in chronic leukaemia (86%) (Supplementary Table S1,
Supplementary Material). There was no difference in distribution
of sex and IMD between those with and without duration of
symptoms data, although data completeness varied slightly by age,
being more complete in younger people (aged 70þ : 90%; aged
50–69: 94%; aged o50: 95%, P¼o0.01).
In total, 423 (21%) patients reported delay in presentation (43
months from first noticing the symptom to first going to see a
doctor).
Risk factors for delay in presentation
Age, sex and socioeconomic status. There was no difference in
frequency of delay by age or sex, although there was a trend
suggesting that older people might be less likely to delay (Table 4).
The most socioeconomically deprived group was most likely to
report delay (29%).
Cancer type. Patients with prostate (48%) and rectal cancer (37%)
were most likely to report delay, and were statistically significantly
more likely to report delay than patients with chronic lymphocytic
leukaemia (chosen as the reference group because the proportion
reporting delay was closest to the pooled average) (Table 5). Eight
percent of women with breast cancer reported delay and this was
the only group statistically significantly less likely to report delay
than patients with chronic lymphocytic leukaemia.
Symptom type. The symptoms statistically significantly associated
with delay in presentation were difficulties with urination (41%),
change of bowel habit (38%), skin symptoms (31%), and systemic
symptoms (29%). There was an association of borderline statistical
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significance between pain and delay in presentation (26%). Patients
reporting lump or swelling were statistically significantly less likely
to have delayed than patients not reporting lump or swelling
(Table 5).
Symptom type was strongly associated with cancer type. Most
patients with urinary difficulties had either prostate or bladder
cancer (84%). Most patients with change of bowel habit (86%) had
cancer of the colon or rectum. Most patients with skin symptoms
(91%) had malignant melanoma or haemato-oncological cancer.
This means that it was not possible to identify whether the
symptom type itself, or some other feature of the cancer, was
causally associated with delay.
Patients with abdominal pain were slightly more likely to
report delay (31%) than those with musculoskeletal pain (25%).
Although bleeding overall was not associated with delay in
presentation, the type of bleeding did appear to be important:
35% of patients with rectal bleeding, 30% of patients with vaginal
bleeding, but only 9% of patients with urinary bleeding delayed
presentation.
Reported reasons for putting off going to the doctor. Patients
who reported that they had not realised that the symptom was
serious were more likely to delay presentation than patients who
did not report this (Table 5). Being too embarrassed to see the
doctor, worry about what the doctor might find, worry about
wasting the doctor’s time and being too busy were all statistically
significantly associated with delay in presentation (Table 5).
Finding it difficult to make an appointment was not associated
with delay in presentation.
Table 3. Frequency of reported reasons for putting off going to the
doctor (1999 patients reporting at least one symptom)
Reported barrier
n (%)
I did not realise the symptom was serious 540 (27.0)
I was worried about wasting the doctor’s time 114 (5.7)
I was worried about what the doctor might find 75 (3.8)
I was too busy to make time to go to the doctor 70 (3.5)
It was difficult to make an appointment with the doctor 48 (2.4)
I was too embarrassed to go to see the doctor 32 (1.6)

















































n n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%) n (%)
Haemato-oncological
Chronic lymphocytic leukaemia 122 22 (18.0) 56 (45.9) 4 (3.3) 2 (1.6) 69 (56.6) 2 (1.6) 20 (16.4) 46 (37.7) 1 (0.8)
Chronic myeloid leukaemia 148 67 (45.3) 9 (6.1) 11 (7.4) 1 (0.7) 104 (70.3) 4 (2.7) 31 (20.9) 50 (33.8) 1 (0.7)
Myeloma 134 88 (65.7) 4 (3.0) 8 (6.0) 1 (0.7) 63 (47.0) 2 (1.5) 13 (9.7) 27 (20.1) 2 (1.5)
Non-Hodgkin’s lymphoma 157 46 (29.3) 89 (56.7) 2 (1.3) 1 (0.6) 63 (40.1) 7 (4.5) 14 (8.9) 33 (21.0) 2 (1.3)
Gastrointestinal
Colon 116 49 (42.2) 2 (1.7) 35 (30.2) 45 (38.8) 49 (42.2) 1 (0.9) 17 (14.7) 3 (2.6)
Rectum 140 30 (21.4) 1 (0.7) 102 (72.9) 29 (20.7) 84 (60.0) 1 (0.7) 4 (2.9)
Gynaecological
Uterus 149 31 (20.8) 1 (0.7) 115 (77.2) 2 (1.3) 31 (20.8) 1 (0.7) 1 (0.7)
Cervix 82 32 (39.0) 1 (1.2) 62 (75.6) 1 (1.2) 20 (24.4) 2 (2.4)
Urogenital
Kidney and ureter 133 54 (40.6) 7 (5.3) 62 (46.6) 22 (16.5) 36 (27.1) 1 (0.8) 19 (14.3)
Bladder 153 33 (21.6) 2 (1.3) 130 (85.0) 48 (31.4) 15 (9.8) 3 (2.0)
Prostate 133 51 (38.3) 13 (9.8) 108 (81.2) 16 (12.0) 2 (1.5) 1 (0.8)
Other
Breast 88 18 (20.5) 72 (81.8) 3 (3.4) 12 (13.6)
Malignant melanoma 151 18 (11.9) 1 (0.7) 133 (88.1) 2 (1.3) 2 (1.3)
Bone or soft tissue sarcoma 135 26 (19.3) 106 (78.5) 1 (0.7) 4 (3.0) 2 (1.5) 2 (1.5) 4 (3.0)
Oral cavity 158 41 (25.9) 67 (42.4) 1 (0.6) 2 (1.3) 17 (10.8)
All 1999 588 (29.4) 435 (21.8) 547 (27.4) 186 (9.3) 500 (25.0) 155 (7.8) 227 (11.4) 207 (10.4) 29 (1.5)
Weighted percentagea 28.5 28.0 23.0 17.6 17.0 10.9 10.3 5.3 0.8
Percentages do not add up to 100 by row because patients may have reported more than one symptom.
aPercentages are weighted for the incidence of cancers among patients reporting the symptom.
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DISCUSSION
Delay in symptomatic presentation for43 months in this group of
cancer patients was common. Delay was more common in people
of lower socioeconomic status. Strong and common risk factors for
delay were prostate cancer, rectal cancer, urinary symptoms,
change of bowel habit, rectal bleeding, systemic symptoms, skin
symptoms and reporting not having recognised the symptoms as
serious.
This survey is unique, as far as we know, in attempting to
quantify symptoms and risk factors for delay in presentation in a
large population of patients with a range of cancers. The design
and reporting were consistent with the Aarhus Statement on early
cancer diagnosis research (Weller et al, 2012).
We excluded some common cancers from the analysis,
including lung, pancreas, stomach and oesophagus. This was
because many of the patients with these cancers had died between
diagnosis and the survey. Those who were alive would have been
an unusual group; including these would have introduced a greater
degree of survivor bias and made our results less generalisable to
the whole population of cancer patients. An important limitation
of our study is that the conclusions are generalisable to patients
with the cancers we have included (who represent about 60% of
cancer patients in the UK) and those who survive for at least a year
after diagnosis.
Older people were underrepresented in our study, perhaps
because they have worse cancer survival (De Angelis et al, 2014)
and are more likely to have died between the Cancer Patient
Experience Survey 2010 and our survey. We cannot, therefore, be
sure that the findings of no association between age and delay in
presentation are reliable. People of non-White ethnic origin were
also underrepresented; all patients in our survey were of White
ethnic origin. This is at least partly because non-White people were
underrepresented in the Cancer Patient Experience Survey 2010
(4% were of non-White origin (Department of Health, 2010),
whereas about 13% of the adult population of England are of
non-White origin (Office for National Statistics, 2013)). We cannot
be sure that our findings would apply to patients of non-White
ethnic group.
Patients may not be able to recall nature and duration of
symptoms, and their reasons for not going to the doctor, accurately
and precisely (Jenkins et al, 2002). Recall error may have caused
bias in our study if people who delayed presentation were more
likely to report reasons for putting off going to the doctor,
perhaps seeking to account for their delay. If this was the case,
however, we might have expected people who delayed presentation
to be more likely to report difficulty in making an appointment as
well as, for example, embarrassment or worry about wasting the
doctor’s time.
We found some evidence that lower socioeconomic position
was a risk factor for delay in presentation. The existing
evidence on the association between low socioeconomic position
and delayed presentation of cancer is conflicting: low socio-
economic position has been found to be a risk factor for delay in
presentation of prostate cancer, but not for delay in presentation
of colorectal cancer or gynaecological cancer (Macleod et al,
2009). This is important because people of low socioeconomic
position have more advanced cancer at diagnosis and worse
survival (Rachet et al, 2010; Lyratzopoulos et al, 2012); why this
is not clear and it may be at least partly due to longer time to
presentation.
Our study has some similar findings to a recently published
study documenting GPs’ reports of cancer patients’ delays in
presentation (Keeble et al, 2014). The definition of a ‘non-prompt’
presentation in that study was duration of symptoms of 15 or more
days; overall about half the patients delayed presentation. As in our
study, delay was less likely in patients with breast or bladder cancer
and more likely in patients with colorectal cancer. However, in
contrast, in that study, prostate cancer was not associated with
delay, and oropharyngeal cancer was associated with delay.
Whether these contrasting results are due to survival bias in our
sample or differences in methods of collecting data on duration of
symptoms is not clear.
A US study also found, as we did, that patients with prostate
cancer were more likely to delay presentation than patients with
breast or colorectal cancer (Samet et al, 1988). Most patients with
prostate cancer in our study reported urinary difficulties (and vice
versa). Urinary difficulties are common in older men with benign
prostatic disease (Kupelian et al, 2006). Although urinary
symptoms may have led to the investigation and diagnosis of
prostate cancer, they may be due to coexisting benign conditions
rather than the cancer.
Rectal cancer has been found in previous studies to be
associated with longer duration of symptoms than colon cancer
(Mitchell et al, 2008). Change in bowel habit, in our study, was
almost exclusively reported by bowel cancer patients, and was
associated with delay in presentation. Change in bowel habit has
been reported to be a risk factor for delay in presentation in
another study (Mor et al, 1990) but another found that it was not a
risk factor (Pedersen et al, 2013). As with urinary difficulties,
change in bowel habit may have an insidious, rather than a
dramatic onset, and for short periods of time at least, may be
regarded as part of normal variation in bodily functions. Similar
issues may explain delay in presentation among patients with skin
symptoms, pain and systemic symptoms, particularly fatigue,
which is very common in the general population (Pawlikowska
et al, 1994; Chou, 2013). Other studies have also suggested
that non-specific symptoms are associated with patient delay
(Macleod et al, 2009). The evidence relating to pain as a risk factor
for patient delay varies by cancer: it is associated with greater delay
in urological cancers, but less delay in gastrointestinal cancers
(Mitchell et al, 2008; Macleod et al, 2009).
Most patients with rectal cancer reported bleeding, most
commonly rectal bleeding, and this was associated with longer
Table 4. Demographic risk factors for delay in presentation (1835 patients








o50 (reference) 71/304 (23.4) 1.00
50–69 217/940 (23.1) 0.99 (0.77–1.25)
70–79 85/391 (21.7) 0.93 (0.69–1.22)
80þ 16/88 (18.2) 0.76 (0.46–1.24)
Sex
Male (reference) 227/985 (23.0) 1.00
Female 196/850 (23.1) 1.00 (0.84–1.18)
Deprivation group
Least deprived (reference) 97/474 (20.5) 1.00
84/437 (19.2) 0.94 (0.73–1.20)
101/406 (24.9) 1.20 (0.95–1.49)
69/293 (23.5) 1.14 (0.88–1.45)
Most deprived 66/208 (28.8) 1.51 (1.18–1.88)
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duration of symptoms, a finding that echoes other studies (Mor
et al, 1990; Pedersen et al, 2013). This is surprising, as it is a
dramatic symptom, and is likely to be due to pathology. However,
we hypothesise that people assume that their bleeding is caused by
haemorrhoids, which affect 4–5% of the adult population
(Johanson and Sonnenberg, 1990).
Delay in presentation in breast cancer has fallen over the last 15
years: a systematic review in 1999 patients reported that 18–29% of
breast cancer patients delayed presentation for 43 months and
reported a decade upon decade fall in the proportion who delayed
presentation up until the 1990s (Westcombe et al, 1999); we found
that only 8% of breast cancer patients delayed presentation. There
is also evidence for gastrointestinal cancers and urological cancer
that patients, over time, are presenting more promptly after onset
of symptoms (MacDonald et al, 2004). This may be due to
increased awareness of cancer symptoms and confidence to seek
help, and broader social changes in the nature of public discourse
about health and cancer, including more openness and less stigma.
We did not find strong evidence that worry about wasting the
doctor’s time or embarrassment can explain the high proportion of
people who report delay in presentation. This contrasts with the
findings of a 2011 survey of people aged 50þ in the UK, in
which 34% reported that worry about wasting the doctor’s time
and 15% that embarrassment might put them off going to a doctor
with a symptom that might be serious (Forbes et al, 2013). What
healthy people think would deter them going to the doctor may not
be the same as what deters them when they actually experience a
symptom.
This study highlights that interventions should ensure that
they are designed to work for people from the lowest socio-
economic groups – although our findings suggest that delay in
presentation is not uncommon in people from higher socio-
economic groups. Approaches to promoting early presentation
should aim to raise awareness of the significance of certain
symptoms, in particular rectal bleeding, because there is a high
risk of delay in presentation, a high positive predictive value
for cancer (Hamilton, 2009) and a low risk of overdiagnosis
of indolent tumours (Welch and Black, 2010). Promoting
awareness of some of the less-specific symptoms, however, such
as urinary difficulties in older men, may expose people to the risk
of overdiagnosis of indolent tumours that would never have
caused harm, or unnecessary tests and anxiety. Our study can
Table 5. Risk factors for delay in symptomatic presentation: cancer type, symptom and reasons for putting off going to the doctor
Delay in presentation Relative risk for delay in presentation (95% CI)
n (%) Unadjusted Adjusteda
Cancer
Prostate 55/115 (47.8) 2.37 (1.52–3.69) 2.93 (1.80–4.79)
Rectum 48/131 (36.6) 1.81 (1.14–2.87) 1.92 (1.16–3.16)
Malignant melanoma 41/142 (28.9) 1.43 (0.89–2.30) 1.62 (0.97–2.70)
Cervix 20/76 (26.3) 1.30 (0.75–2.26) 1.11 (0.59–2.12)
Uterus 40/139 (28.8) 1.42 (0.88–2.30) 1.44 (0.85–2.46)
Colon 27/108 (25.0) 1.24 (0.74–2.08) 1.46 (0.83–2.54)
Chronic myeloid leukaemia 33/137 (24.1) 1.19 (0.72–1.96) 1.20 (0.70–2.07)
Bone or soft tissue sarcoma 28/127 (22.0) 1.09 (0.65–1.83) 1.10 (0.62–1.93)
Chronic lymphocytic leukaemia (Reference) 19/94 (20.2) 1.00 1.00
Kidney and ureter 22/123 (17.9) 0.88 (0.51–1.54) 1.00 (0.58–1.08)
Non-Hodgkins lymphoma 26/150 (17.3) 0.86 (0.50–1.46) 0.92 (0.52–1.63)
Myeloma 18/119 (15.1) 0.75 (0.42–1.34) 0.65 (0.34–1.26)
Oral cavity 22/147 (15.0) 0.74 (0.42–1.29) 0.77 (0.43–1.40)
Bladder 17/144 (11.8) 0.58 (0.32–1.06) 0.71 (0.37–1.34)
Breast 7/83 (8.4) 0.42 (0.18–0.94) 0.41 (0.18–0.96)
Presenting symptom. Reference: those who did not report the symptom
Difficulties with urination 68/167 (40.7) 1.91 (1.55–2.30) 2.12 (1.70–2.56)
Change of bowel habit 56/146 (38.4) 1.77 (1.40–2.16) 1.82 (1.42–2.25)
Skin symptoms 64/207 (30.9) 1.40 (1.11–1.73) 1.42 (1.11–1.78)
Systemic symptoms 131/460 (28.5) 1.34 (1.12–1.58) 1.33 (1.10–1.59)
Pain 144/551 (26.1) 1.20 (1.01–1.42) 1.19 (0.98–1.42)
Chest symptoms 48/189 (25.4) 1.11 (0.85–1.43) 1.08 (0.80–1.40)
Bleeding 124/524 (23.7) 1.04 (0.86–1.24) 1.03 (0.84–1.24)
Eating-related 6/28 (21.4) 0.93 (0.43–1.75) 0.91 (0.42–1.75)
Lump or swelling 69/411 (16.8) 0.68 (0.53–0.85) 0.61 (0.47–0.79)
Reasons for putting off going to the doctor. Reference: those who did not report the reason
I was too embarrassed to go to see the doctor 21/31 (67.7) 3.04 (2.22–3.67) 3.07 (2.17–3.77)
I was too worried about what the doctor might find 40/70 (57.1) 2.63 (2.08–3.15) 2.62 (2.02–3.19)
I was too busy to make time to go to the doctor 34/69 (49.3) 2.24 (1.70–2.78) 2.31 (1.73–2.89)
I did not realise the symptom was serious 195/512 (38.1) 2.21 (1.91–2.53) 2.24 (1.91–2.58)
I was worried about wasting the doctor’s time 41/109 (37.6) 1.70 (1.30–2.14) 1.54 (1.13–2.01)
It was difficult to make appointment with doctor 12/46 (26.1) 1.14 (0.66–1.77) 1.18 (0.68–1.85)
aFor age, sex and deprivation group.
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contribute to policy on promoting early diagnosis of cancer,
and to the government’s ambition to improve cancer survival in
the UK.
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